Evaluation of hepatitis B virus screening and reactivation in patients with hematological malignancies receiving rituximab-based chemoimmunotherapy: A single-center retrospective study
Journal of Oncology Pharmacy Practice, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Basım Tarihi: 2026
- Doi Numarası: 10.1177/10781552261441845
- Dergi Adı: Journal of Oncology Pharmacy Practice
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
- Anahtar Kelimeler: rituximab, hepatitis B reactivation, B-cell lymphoproliferative neoplasm
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction: Hepatitis B reactivation (HBVr) is a serious problem in patients with B-cell lymphoproliferative neoplasms receiving rituximab-based chemoimmunotherapy. This retrospective study aimed to evaluate the use of hepatitis B virus (HBV) screening and antiviral prophylaxis. Methods: Data from 577 patients treated between 2000 and 2017 were retrospectively analyzed, and screening efficacy before and after 2010 was compared. Results: HBsAg, anti-HBs and anti-HBc IgG screening were determined as effective screening, and a significant improvement was achieved in effective screening in the second period. 47 patients received antiviral prophylaxis. 16 of 18 (3.1%) patients with HBVr were not receiving prophylaxis. The mean time to reactivation was 18.1 months after the start of chemoimmunotherapy, and one patient (0.2%) died of HBVr. Conclusions: The findings highlight the critical importance of pretreatment HBV screening and prophylaxis to protect patients from the adverse consequences of reactivation. The study concludes that lamivudine may be a suitable prophylaxis option in selected patients.